Search Results: Xofigo

Redirect to:

Radium-223
Kamis, 2025-11-06 07:14:05

Norwegian company Algeta ASA, in a partnership with Bayer, under the trade name Xofigo (formerly Alpharadin), and is distributed as a solution containing radium-223...

Click to read more »
Algeta
Rabu, 2026-05-27 06:43:23

alpha-particle emitting radiopharmaceuticals. The lead product of the company, Xofigo is the first marketed alpha-particle emitting radiopharmaceutics for cancer...

Click to read more »
Radioligand
Senin, 2026-06-29 14:20:47

cells expressing PSMA, but Xofigo attacks all bone metastases. Qualified patients are 30% less likely to die when treated by Xofigo than if treated by a placebo...

Click to read more »
Radium
Senin, 2026-08-10 17:53:42

radiation drug Xofigo from Bayer, Algeta". Retrieved 1 October 2014.{{cite web}}: CS1 maint: deprecated archival service (link) "FDA approves Xofigo for advanced...

Click to read more »
Bayer
Selasa, 2026-08-11 21:25:28

were Xarelto (rivaroxaban), Eylea (aflibercept), Stivarga (regorafenib), Xofigo (radium-223), and Adempas (riociguat). Top-selling products as of 2014 included:...

Click to read more »
HealthCap
Selasa, 2026-06-16 21:57:33

med-tech products to the market. Many of these products, such as Firazyr®, Xofigo®, Tracleer®, are breakthrough therapies addressing life-threatening diseases...

Click to read more »
Radium chloride
Minggu, 2026-06-21 06:50:25

treatment. Radium-223 dichloride (USP, radium chloride Ra 223), tradename Xofigo (formerly Alpharadin), is an alpha-emitting radiopharmaceutical. Bayer received...

Click to read more »
List of drugs: X
Jumat, 2026-01-09 06:20:02

xinomiline (INN) xipamide (INN) Xipere xipranolol (INN) Xiral Xoanacyl Xocova Xofigo Xofluza Xolair Xolegel Xolremdi Xopenex Hfa Xopenex xorphanol (INN) Xospata...

Click to read more »
Management of prostate cancer
Kamis, 2026-08-20 00:19:37

therapy in patients with hormone-refractory metastatic prostate cancer. Xofigo is a new alpha-emitting pharmaceutical targeting bone metastasis. Phase...

Click to read more »